Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAK694 plus subcutaneous allergen immunotherapy for seasonal allergic rhinitis
2009-013429-40Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in seasonal allergic rhinitis (SAR) and allergic rhinitis (AR) comparing VAK694 + Alutard Avanz with Placebo + Alutard Avanz (2 arms). Primary endpoints: Sustained suppression of the late phase cutaneous response to allergen and Late Phase Response. Started Sep 2009; status: completed.
02
Drugs
vak694Alutard Avanz
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2009-013429-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013429-40.